RYSTIGGO

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Lithuania, Romania.

Active ingredients

The drug RYSTIGGO contains one active pharmaceutical ingredient (API):

1	Rozanolixizumab UNII P7186074QC - ROZANOLIXIZUMAB
	Rozanolixizumab is a humanised IgG4 monoclonal antibody that decreases serum IgG concentration by inhibiting the binding of IgG to FcRn, a receptor that under physiological conditions protects IgG from intracellular degradation and recycles IgG back to the cell surface. By the same mechanism, rozanolixizumab decreases the concentration of pathogenic IgG autoantibodies associated with generalised myasthenia gravis (gMG).
	Read more about Rozanolixizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
RYSTIGGO Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
RYSTIGGO Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AG16		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG16

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3062966
FR	Base de données publique des médicaments	68822785
LT	Valstybinė vaistų kontrolės tarnyba	1098627
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W70053001
US	FDA, National Drug Code	50474-980